首页> 外文期刊>Trials >A novel hand-assisted laparoscopic versus conventional laparoscopic right hemicolectomy for right colon cancer: study protocol for a randomized controlled trial
【24h】

A novel hand-assisted laparoscopic versus conventional laparoscopic right hemicolectomy for right colon cancer: study protocol for a randomized controlled trial

机译:新型手工辅助腹腔镜与常规腹腔镜右半结肠切除术治疗右结肠癌:一项随机对照试验的研究方案

获取原文
           

摘要

Background Although conventional laparoscopic and hand-assisted laparoscopic surgery for colorectal cancer is widely used today, there remain many technical challenges especially for right colon cancer in obese patients. Herein, we develop a novel hand-assisted laparoscopic surgery (HALS) with complete mesocolic excision (CME), D3 lymphadenectomy, and a total “no-touch” isolation technique (HALS-CME) in right hemicolectomy to overcome these issues. According to previous clinic practice, this novel procedure is not only feasible and safe but has several technical merits. However, the feasibility, short-term minimally invasive virtues, long-term oncological superiority, and potential total “no-touch” isolation technique benefits of HALS-CME should be confirmed by a prospective randomized controlled trial. Methods/design This is a single-center, open-label, noninferiority, randomized controlled trial. Eligible participants will be randomly assigned to the HALS-CME group or to the laparoscopic surgery with CME, D3 lymphadenectomy, and total “no-touch” isolation technique (LAP-CME) group, or to conventional laparoscopic surgery with CME and D3 lymphadenectomy (cLAP) group at a 1:1:1 ratio using a centralized randomization list. Primary endpoints include safety, efficacy, and being oncologically clear, and 3-year disease-free, progression-free, and overall survival. Second endpoints include operative outcomes (operation time, blood loss, and incision length), pathologic evaluation (grading the plane of surgery, length of proximal and distal resection margins, distance between the tumor and the central arterial high tie, distance between the nearest bowel wall and the same high tie, area of mesentery resected, width of the chain of lymph-adipose tissue, length of the central lymph-adipose chain, number of harvested lymph nodes), and postoperative outcomes (pain intensity, postoperative inflammatory and immune responses, postoperative recovery). Discussion This trial will provide valuable clinical evidence for the feasibility, safety, and potential total “no-touch” isolation technique benefits of HALS-CME for right hemicolectomy. The hypothesis is that HALS-CME is feasible for the radical D3 resection of right colon cancer and offers short-term safety and long-term oncological superiority compared with conventional laparoscopic surgery. Trial registration ClinicalTrials.gov, NCT02625272 . Registered on 8 December 2015.
机译:背景技术尽管当今广泛使用用于大肠癌的常规腹腔镜和手助腹腔镜手术,但是仍然存在许多技术挑战,特别是对于肥胖患者的右结肠癌。本文中,我们开发了一种新颖的手助腹腔镜手术(HALS),其中包括完全中脑切除(CME),D3淋巴结清扫术和右半结肠切除术中的全“非接触式”隔离技术(HALS-CME),以克服这些问题。根据以前的临床实践,这种新颖的方法不仅可行且安全,而且具有多种技术优点。但是,HALS-CME的可行性,短期微创优势,长期肿瘤学优势以及潜在的总“无接触”隔离技术优势应通过一项前瞻性随机对照试验予以证实。方法/设计这是一项单中心,开放标签,非劣效,随机对照试验。符合条件的参与者将被随机分配到HALS-CME组或CME,D3淋巴结清扫术和全“非接触式”隔离技术(LAP-CME)的腹腔镜手术组,或CME和D3淋巴结清扫术的常规腹腔镜手术( cLAP)组使用集中式随机列表以1:1:1的比例进行分组。主要终点指标包括安全性,疗效和在肿瘤学上明确的指标,以及3年无病,无进展和总生存期。第二个终点包括手术结果(手术时间,失血量和切口长度),病理学评估(手术平面分级,近端和远端切除切缘的长度,肿瘤与中央动脉高束缚带之间的距离,最近的肠之间的距离)壁和相同的高领带,切除的肠系膜区域,淋巴脂肪组织链的宽度,中央淋巴脂肪链的长度,收获的淋巴结的数量)以及术后结果(疼痛强度,术后炎症和免疫反应) ,术后恢复)。讨论该试验将为HALS-CME在右半结肠切除术中的可行性,安全性和潜在的“无接触”隔离技术带来的潜在总价值提供有价值的临床证据。假说是,与传统的腹腔镜手术相比,HALS-CME可用于右结肠癌的D3根治性根治术,并且具有短期安全性和长期肿瘤学优势。试用注册ClinicalTrials.gov,NCT02625272。 2015年12月8日注册。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号